Profiles

Keywords
Last Name
Institution

Jamile Shammo

TitleAssociate Professor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Hematology/Oncology/Cell Therapy
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 8704664200.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Elliott E, Waheed S, Syed S, Eswaran S, Gregory S, Shammo J. Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab. Clin Lymphoma Myeloma Leuk. 2017 Oct 07. PMID: 29102415.
      View in: PubMed
    2. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017 Jun 26; 10(1):131. PMID: 28651604.
      View in: PubMed
    3. Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int J Mol Sci. 2017 Apr 14; 18(4). PMID: 28420120.
      View in: PubMed
    4. Karmali R, Larson ML, Shammo JM, Gregory SA, O'Brien T, Venugopal P. Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. Mol Clin Oncol. 2017 Apr; 6(4):627-633. PMID: 28413681.
      View in: PubMed
    5. Shammo JM, Stein BL. Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):552-560. PMID: 27913528.
      View in: PubMed
    6. Chalmers AW, Shammo JM. Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Ther Clin Risk Manag. 2016; 12:201-8. PMID: 26929633; PMCID: PMC4760653.
    7. Karmali R, Larson ML, Shammo JM, Basu S, Christopherson K, Borgia JA, Venugopal P. Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42. PMID: 25735964.
      View in: PubMed
    8. Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013 Sep; 54(9):1989-95. PMID: 23245211.
      View in: PubMed
    9. Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am J Med. 2012 Jul; 125(7 Suppl):S6-13. PMID: 22735753.
      View in: PubMed
    10. Gregory SA, Mesa RA, Hoffman R, Shammo JM. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol. 2011 Sep; 9(9 Suppl 22):1-16. PMID: 22362131.
      View in: PubMed
    11. Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011 Nov; 52(11):2097-104. PMID: 21702643.
      View in: PubMed
    12. Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74. PMID: 21700527.
      View in: PubMed
    13. Shammo JM, Foran JM, Houk A, Epstein J, Narang M, Rubinstein P, Dennison B, Latsko JM, Naganna G. An examination of educational gaps in the diagnosis and treatment of myelodysplastic syndromes. Cancer Control. 2011 Jan; 18(1):65-74. PMID: 21273982.
      View in: PubMed
    14. Cela I, Miller IJ, Katz RS, Rizman A, Shammo JM. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE). Clin Adv Hematol Oncol. 2010 Nov; 8(11):806-9. PMID: 21326158.
      View in: PubMed
    15. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010 Feb 20; 28(6):1038-46. PMID: 20085936; PMCID: PMC2834429.
    16. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010 Jan 20; 28(3):437-44. PMID: 20008626.
      View in: PubMed
    17. Shammo JM. Clinical roundtable monograph. MDS classification and risk stratification. Clin Adv Hematol Oncol. 2009 Jul; 7(7):S8-12. PMID: 19731465.
      View in: PubMed
    18. Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P. Idiopathic hemophagocytic syndrome with a fulminant clinical course. Clin Adv Hematol Oncol. 2008 Aug; 6(8):587-90. PMID: 18820601.
      View in: PubMed
    19. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008 Jan 01; 111(1):86-93. PMID: 17893227.
      View in: PubMed
    20. Rao R, Shammo JM, Enschede SH, Porter C, Adler SS, Venugopal P, Gregory SA. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma. Clin Lymphoma. 2005 Jun; 6(1):26-30. PMID: 15989703.
      View in: PubMed
    Shammo's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description